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Abstract
The pro-inflammatory cytokine interleukin-1 (IL-1) plays a key role in many physiological processes and during the
inflammatory and immune response to most common diseases. IL-1 exists as two agonists, IL-1α and IL-1β that
bind to the only signaling IL-1 type 1 receptor (IL-1R1), while a second decoy IL-1 type 2 receptor (IL-1R2) binds
both forms of IL-1 without inducing cell signaling. The field of immunology and inflammation research has, over
the past 35 years, unraveled many mechanisms of IL-1 actions, through in vitro manipulation of the IL-1 system or
by using genetically engineered mouse models that lack either member of the IL-1 family in ubiquitous constitutive
manner. However, the limitation of global mouse knockout technology has significantly hampered our understanding
of the precise mechanisms of IL-1 actions in animal models of disease. Here we report and review the recent
generation of new conditional mouse mutants in which exons of Il1a, Il1b, Il1r1, and Il1r2 genes flanked by
loxP sites (fl/fl) can be deleted in cell-/tissue-specific constitutive or inducible manner by Cre recombinase expres-
sion. Hence, IL-1αfl/fl, IL-1βfl/fl, IL-1R1fl/fl, and IL-1R2fl/fl mice constitute a new toolbox that will provide a step
change in our understanding of the cell-specific role of IL-1 and its receptor in health and disease and the potential
development of targeted IL-1 therapies.
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Introduction
Interleukin-1 is a master pro-inflammatory cytokine implicat-
ed in a wide range of physiological processes including devel-
opment [1], regulation of neuroimmune and neuroendocrine
functions [2], and central processes such as sleep and memory
[3] and plays a key role in the initiation and orchestration of
the inflammatory response to most, if not all, pathological
inflammatory conditions, including infections and non-
communicable diseases such as atherosclerosis or stroke (see
[4] for review). The IL-1 family comprises two IL-1 agonists
(IL-1α and IL-1β) and the naturally IL-1 receptor antagonist
(IL-1Ra) that bind primarily to the IL-1 type 1 receptor (IL-
1R1) and IL-1 receptor accessory protein (IL-1RAcP) leading
to cell signaling (reviewed in [5]), while a second IL-1 type 2
receptor (IL-1R2) binds both IL-1 isoforms without inducing
cell signaling, acting therefore as a decoy receptor [6].
Since their discovery, IL-1α and IL-1β are believed to
have similar and often overlapping biological functions, since
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they bind to the same receptor inducing similar cell signaling
mechanisms. However, there are marked differences in the
regulation of expression and mechanisms of actions of these
two cytokines. Although both isoforms require enzymatic
cleavage for generation of their mature forms, IL-1β is the
main secreted isoform, whereas IL-1α remains cytoplasmic
but can also be released during cell death or by mechanisms
that are different from that of IL-1β (reviewed in [7]).
Furthermore, both IL-1α and IL-1β have been thought to
exert similar biological activities primarily through binding
to IL-1R1. However, several previous studies have demon-
strated differential actions of both cytokines in various para-
digms of inflammation; for instance, IL-1α and IL-1β exert
differential potency at inducing fever when administered ex-
ogenously [8], while IL-1α, but not IL-1β, triggers sepsis
lethality in mouse [9] and is required for T cell activation
during allergen-induced hypersensitivity [10]. Further, IL-
1α, but not IL-1β, induces brain cells to generate the LG3
neuroprotective protein fragment of the extracellular matrix
component perlecan, a prominent component of the blood-
brain barrier [11]. Of interest, polymorphisms in the human
Il1a, but not Il1b gene, is associated with higher incidence of
vascular malformation and/or higher risk of ischemic stroke
[12, 13]. In contrast, IL-1β, but not IL-1α, activates IL-6
expression in neurons [14], selectively mediates the response
to vascular injury [15], while IL-1α- and IL-1β-specific ac-
tions have also been identified in acute colon inflammation in
mice [16]. Taken together, these observations suggest that IL-
1α and IL-1β may be differentially expressed during inflam-
mation and may exert non-overlapping ligand-specific differ-
ential actions dependent on the disease paradigm.
Mouse genetic models to understand the role
of IL-1α and IL-1β in disease
For decades, the field of inflammation research has unraveled
key mechanisms of IL-1 actions using traditional global gene
targeting knockout technology in animal models. Indeed, IL-
1α-deficient (−/−), IL-1β−/−, and IL-1α/β−/− (as well as IL-
1Ra−/−) mice generated by Horai and collaborators in 1998
[17] have proven useful to identify some selective mecha-
nisms of actions of both isoforms in some pathological con-
ditions. In those genetic models, disruption of the Il1a and
Il1b genes was achieved by deletion of the NH2-terminal cod-
ing region for mature IL-1α (exon 5–intron 5) and IL-1β
(exon 3–5), leading to ubiquitous constitutive inhibition of
expression of either genes. These genetic models have been
used widely in many disease models and have subsequently
led to the identification of some IL-1α- and IL-1β-specific
mechanisms as described above. Further, IL-1R1−/− mice,
originally generated by Immunex by targeted deletion of exon
1 and 2 of the Il1r1 gene [18], showed that most, but not all,
IL-1 actions are mediated by IL-1R1 (see [19] for review).
Indeed, studies using IL-1R1−/− mice in animal models of
gut infection with helminth Trichuris muris [20] and experi-
mental stroke [21] found that IL-1β can function in an IL-
1R1-independent manner, while IL-1β exacerbates neuronal
apoptosis caused by status epilepticus through a mechanism
independent of IL-1R1 [22]. Further, some neuroprotective
actions of IL-1 are believed to be triggered independently of
IL-1R1 via activation of the neuroprotective PI3K/Akt signal-
ing pathway [23], while we have reported IL-1R1-
independent IL-1 actions in glial cells [24]. Those IL-1R1-
independent actions, primarily observed in the original IL-
1R1−/− mice, are known to be mediated through a spliced
variant of the Il1r1 gene leading to a truncated IL-1R1 isoform
still expressed upon exon 1–2 deletion, due to the activation of
an additional internal promoter positioned upstream of exon
1–2 [25]. This truncated isoform of the receptor has been fully
characterized and lacks part of the extracellular IL-1 binding
region but is still capable of inducing an intracellular signal in
response to IL-1 that is known to mediate the neuroprotective
actions of IL-1 in the brain via activation of the PI3K/Akt
pathways [25]. Ubiquitous Il1rap gene deletion, that encodes
IL-1RAcP, has also been achieved in mice, by targeting exon
D1 and part of exon D2 that encode the first Ig-like and part of
the second Ig-like extracellular domains, resulting in complete
inhibition of IL-1 signaling in response to IL-1α and IL-1β
[26]. In accordance with the phenotypic responses observed in
IL-1R1− /− mice, IL-1RAcP− /− mice show reduced
neuroimmune and febrile responses to IL-1 [27, 28]. Finally,
IL-1R2−/− mice in which exon 2–4 are deleted using conven-
tional gene targeting method have also been generated [29].
These mice show increased susceptibility to collagen-induced
arthritis, while IL-1β-induced cytokine response was en-
hanced in macrophages. In agreement with its inhibitory func-
tion, IL-1Ra−/−mice develop spontaneous autoimmune arthri-
tis [30] and psoriasis-like cutaneous inflammation [31] and
show increased brain injury to experimental stroke [32] and
atherosclerotic lesion in experimental atherosclerosis [33].
Taken together, these observations demonstrate the complex-
ity of the IL-1 system and point to important, yet undiscov-
ered, mechanisms of actions of IL-1 ligands and their recep-
tors, which cannot be explored by using classical pharmaco-
logical or genetic approaches.
Generation of a new toolbox to allow
cell-specific conditional deletion of IL-1
ligands and their receptors
Germline gene deletion in mice has yielded important discov-
eries regarding the role of IL-1 ligands and their receptors in
various inflammatory paradigms. However, this approach has
important limitations such as viability and fertility of progeny,
924 J Mol Med (2020) 98:923–930
subtle phenotypic changes, and/or compensatory mechanisms
that may alter steady-state immune responses. In relation to
the IL-1 system, IL-1α−/−, IL-1β−/−, IL-1R1−/−, IL-1RAcP−/−,
and IL-1R2−/−mice have all been reported to be viable with no
obvious altered fertility. However, some reports suggested
that IL-1 regulates ovulation, oocyte maturation, and early
embryonic development [34, 35], which could lead to long-
term significant phenotypic changes. Indeed, normal bone
growth and remodeling are altered in IL-1R1−/− and IL-1α/
β−/−mice [36, 37], whereas decrease body fat mass is reduced
in IL-1Ra−/− mice [38], strongly suggesting that significant
phenotypic changes occur after ubiquitous deletion of IL-1
family members. Finally, significant compensatory changes
are known to occur after ubiquitous gene deletion, and micro-
array analysis demonstrated that expression of several genes is
altered in IL-1R1−/−mice [24]. To overcome these limitations,
the Cre/loxP system that allows selective/conditional deletion
of targeted genes was recently used to generate new mouse
mutant lines to allow cell-specific conditional deletion of IL-1
ligands and its receptors in a Cre recombinase-dependent
manner (loxP-flanked, abbreviated as fl/fl). To this end, we
have recently reported the generation and characterization of
new IL-1αfl/fl and IL-1βfl/fl mouse lines [39, 40] generated
from Il1atm1a(EUCOMM)Wtsi (clone EPD0822-4-H02) or
Il1btm1a(EUCOMM)Hmgu (clone HEPD0840-8-E03) embryonic
stem cells purchased from the European Mouse Mutant Cell
Repository (EuMMCR). The full description of the gene
targeting strategies for both IL-1αfl/fl and IL-1βfl/fl mice as
well as experimental procedure from initial culturing and mi-
croinjection of ES cells leading to the generation of mice
allowing for the conditional deletion of IL-1α and IL-β are
published [39, 40]. In these new alleles, exon 4 of the Il1a
gene (for IL-1αfl/fl mice) or exon 4–5 of the Il1b gene (for IL-
1βfl/fl mice) flanked with loxP sites can be deleted by Cre
recombinase, leading to exon 4 or 4–5 deletion and generation
of cell-specific IL-1α and IL-1β-deficient allele, respectively
(Fig. 1A and B).
Recently, two new mouse mutants, allowing for the condi-
tional deletion of Il1r1 (IL-1R1fl/fl), have been described.
Robson and collaborators [41] have generated a new IL-
1R1fl/fl, in which exon 3–4 of the Il1r1 gene (encoding part
of the extracellular binding region) can be deleted by Cre
recombination and demonstrated ubiquitous inhibition of IL-
1R1 signaling by the crossing of the conditional allele to the
CMV-Cre mice, which mediated recombination in early em-
bryogenesis. Concomitantly, we have generated a new IL-
1R1fl/fl mouse (developed by Taconic, Cologne, Germany),
in which exon 5 that also encodes part of the extracellular
binding region of the receptor is flanked by LoxP sites [42]
(Fig. 1C). In those two new IL-1R1 mutants, deletion of exon
3–4 or exon 5 inactivates the two previously described func-
tional IL-1R1 gene transcripts (including the full-length IL-
1R1 and truncated IL-1R3) upon Cre- mediated
recombination [25]. In our study, we have also reported the
generation of a new ubiquitous IL-1R1−/− mouse as well as
myeloid cell-specific IL-1R1-deficient mice by crossing IL-
1R1fl/fl with mice expressing Cre recombinase under the pro-
moter of keratin 14 (K14-Cre) and the Vav promoter, respec-
tively [42]. Of importance, an advanced genetic tool based on
restoration of Il1r1 gene expression has been developed by
Liu and collaborators [43]. In this advanced model, excision
of a disruptive intronic sequence in the Il1r1 gene under Cre
recombination in a global IL-1R1−/− background allows func-
tional restoration of IL-1 signaling under cell-specific pro-
moters and has been important in the discovery of mecha-
nisms of IL-1 signaling in the brain in the broad context IL-
1-driven central inflammation [44]. Finally, generation of IL-
1R2fl/fl targeting exon 3 of the Il1r2 gene was also reported
[45], and we now report in our hand the generation of a similar
IL-1R2fl/fl mouse that targets exon 3 of Il1r2 gene and further
generation of IL-1R2−/− by crossing IL-1R2fl/fl with mice ex-
pressing Cre recombinase under the promoter of keratin 14
(K14-Cre) (Fig. 2A).
Generation of IL-1R2fl/fl and IL-1R2−/− mice
IL-1R2 conditional (IL-1R2fl/fl) mice were generated at
Taconic (Cologne, Germany) by gene targeting using BAC
clones as the targeting vector from the C57BL/6J RPCI-23
BAC library encoding two loxP sites flanked exon 3 of the
Fig. 1 Generation of IL-1αfl/fl, IL-1βfl/fl, and IL-1R1fl/fl mice. A Exon 4
of the Il1a gene (for IL-1α fl/fl),B exon 4–5 of the Il1b gene (for IL-1β fl/fl
mice), or C exon 5 of the Il1r1 gene (for IL-1R1fl/fl) flanked with loxP
sites is excised upon Cre recombination, resulting in cell-specific IL-1α-,
IL-1β-, or IL-1R1-deficient allele, respectively
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Il1r2 gene and subsequent homologous recombination in
C57BL/6 N embryonic stem (ES) cells. From targeted
C57BL/6 N ES cells, as verified by southern blotting, chime-
ric mice were generated and bred to C57BL/6 females.
Germline transmission was identified by genotyping PCR
sample analysis using a Caliper LabChip GX device (details
are available upon request). Genotyping identification of IL-
1R2fl/fl mice was carried out on genomic DNA by PCR (see
Fig. 2B) (details of primers used in Fig. 2 legend and protocol
of DNA amplification available upon request). Amplification
product size obtained were as follows: wild type (228 bp) and
IL-1R2fl/fl (347 bp).
A new ubiquitous IL-1R2−/− mouse was generated by
crossing the IL-1R2fl/fl mice with mice expressing Cre
recombinase under the control of the human keratin 14 pro-
moter in oocytes as described [46], leading to genetic deletion
of exon 3 in all tissues. The deletion of exon 3 causes a frame
shift from exon 4 to all downstream exons. Genotypic
identification of exon 3 deletion in IL-1R2−/−mice was carried
out by PCR on isolated genomic DNA (see Fig. 2C) (details of
primers used in figure legend and protocol of DNA amplifi-
cation available upon request).
Advanced discoveries in mechanisms of IL-1
actions in disease using the toolbox
The new toolbox comprising IL-1αfl/fl, IL-1βfl/fl, IL-1R1fl/fl,
and IL-1R2fl/fl mice allows for the first time the generation of
newmouse lines in which IL-1 and its receptors can be deleted
in a cell/tissue specific manner. To date, IL-1αfl/fl, IL-1βfl/fl,
IL-1R1fl/fl, and IL-1R2fl/fl mice have been crossed with spe-
cific Cre drivers leading to cell- or tissue-specific deletion of
either gene in a constitutive (Cre) or inducible (Cre-ER) man-
ner, revealing new mechanisms of IL-1 actions. Table 1 pro-
vides a list of the cell-/tissue-specific deficient mice in IL-1α,
IL-1β, IL-1R1, and IL-1R2 generated to date that have been
tested under different inflammatory paradigms. While the
generation of cell-specific IL-1α and IL-1β-deficient lines is
limited, due to the recent generation of IL-1αfl/fl and IL-1βfl/fl
mice, the first studies using those models have demonstrated
the critical role of microglial IL-1β in the establishment of
pain in the context of complex regional pain syndrome [39],
while cardiomyocyte-derived IL-1α has been found not to
contribute to tissue remodeling during myocardial infarction
[40]. In contrast, IL-1R1fl/fl mice have generated various cell-/
tissue-specific IL-1R1-deficient lines, most studies showing a
critical role for IL-1 signaling in immune cell activation and
vascular activation in various models of peripheral infection
and chronic inflammation (see Table 1). For instance, IL-1
signaling in cells of the hematopoietic lineage is required for
the IL-17 and IL-22 response to gut infection by the nematode
Trichuris Muris [42], whereas IL-1 signaling in T cells [50]
and in GM-CSF producing cells [52] plays a critical role in
experimental autoimmune encephalomyelitis. Furthermore,
IL-1 signaling in T cells plays a key role in the systemic
immune response to injection of CD3 antibodies [49].
Inhibition of IL-1 signaling by ColVI-Cre driver in intestinal
mesenchymal cells showed that IL-1R1 in these cells has no
important role in the development of intestinal carcinogenesis
[60]. Furthermore, no direct role of IL-1 signaling in CD45+
hematopoietic was found in IL-1-mediated resistance to
Mycobacterium tuberculosis [62]. In contrast, IL-1R1 on he-
patocytes reduces liver injury in a model of acute liver failure
[61], while deletion of IL-1R1 in pancreatic cells alters glu-
cose homeostasis and triggers β-cell de-differentiation [57].
Finally, a study using Ly6G-Cre mice found that IL-1R1 in
neutrophils plays a key role in reducing the tumorigenic ef-
fects of IL-1 [51]. In peripheral vascular beds, cadherin-Cre
mediated IL-1R1 deletion in endothelial cells contributes to
the anti-tumor function of adoptively transferred T cells
Fig. 2 Generation of IL-1R2fl/fl and IL-1R2−/−mice.A Genetic approach
to generate IL-1R2fl/fl mice was designed to induce deletion of exon 3
encoding part of the extracellular binding domain, generating a frameshift
from exon 4 to all downstream exons leading to genetic inhibition of IL-
1R2. B Genotyping identification of IL-1R2fl/fl mice was carried out by
PCR using the following primers: Forward, TGTCTCCATCAGAC
TGACTTTAGG, depicted (1), and reverse, ACCATGTCTGCCTG
TTCACC, depicted (2) on genomic DNA. Amplification product size
obtained was as follows: wild type (228 bp) and IL-1R2fl/fl (347 bp). C
Genotypic identification of exon 3 deletion in IL-1R2−/− mice (obtained
by crossing IL-1R2fl/fl mice with mice expressing Cre recombinase under
a keratin 14 promoter) was carried out by PCR on isolated genomic DNA
using the following primers: Forward, GTAGTGGGCAATCA
GATGGAC, depicted (3), and reverse, ACCATGTCTGCCTG
TTCACC, depicted (2). Amplification product size obtained was
300 bp in the IL-1R2−/− mice after Cre recombination
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regulated by IL-1β [63], whereas IL-1R1 signaling in smooth
muscle cells contributes to the atheroprotective effect of IL-1
in advanced atherosclerotic lesions [56].
In the brain, IL-1 signaling in microglia is required for the
renewal properties of microglial progenitor cells [53]. Brain
endothelial IL-1R1 is essential in the initiation of the fever
Table 1 List of cell-/organ-specific deficient mice for IL-1 isoforms or their receptors and main effects observed
Gene Cre driver Cell/tissue targeted Main effects References
Il1a Myh6-Cre Cardiomyocytes No effect on cardiac tissue remodeling after MI Bageghni et al. [40]
Il1b CMV-Cre Ubiquitous deletion Reduces bone metastasis during breast cancer Tulotta et al. [47]
CX3CR1-CreER Microglial cell Reduces the development of pain [39]
Il1r1 K14-Cre Ubiquitous deletion Mediates peripheral immune response to T. Muris infection [42]
Inhibits melanoma inflammatory niche Young et al. [48]
CMV-Cre Ubiquitous deletion Decreases inflammatory responses to systemic challenges Mufazalov et al. [49];
Mufazalov et al. [50]
NI Robson et al. [41]
PGK-Cre Ubiquitous deletion Regulates cardiac tissue remodeling after MI Bageghni et al. [40]
Col1a2-CreER Fibroblasts Regulates cardiac tissue remodeling after MI Bageghni et al. [40]
CD4-Cre T cells Regulates immune response to CD3 antibody injection Mufazalov et al. [49]
Regulates neuroinflammation in EAE Mufazalov et al. [50]
Vav-Cre Myeloid cells Mediates peripheral immune response to T. Muris infection Adbulaal et al. [42]
Ly6G-Cre Neutrophils Reduces the tumorigenic effect of IL-1 Dmitrieva-Posocco et al. [51]
Csf2-Cre GM-CSF positive
cells
Regulates inflammation after EAE Komuczki et al. [52]
CX3CR1-CreER Microglial cells Reduces renewal of microglial population Bruttger et al. [53]
Regulates microglial activation after CNS inflammation Zhu et al. [54]*
No effect on febrile response to IL-1 Knoll et al. [55]*
Myh11-CreER Smooth muscle cells Reduces atheroprotective effect of IL-1 after atherosclerosis Gomez et al. [56]
Pdx1-Cre Pancreatic cells Alters glucose homeostasis and triggers β-cell de-differentiation Burke et al. [57]
Slco1c1-CreER Brain endothelial
cells
Reduces CNS inflammation and brain damage after stroke Wong et al. [58]
Reduces fever response to IL-1 Matsuwaki et al. [59]
Nestin-Cre Neuronal cells No effect on febrile response to IL-1 Matsuwaki et al. [59]
Reduces brain damage after stroke Wong et al. [58]
Trpv1-Cre Nociceptor sensory
neurons
No effect on febrile response to IL-1 Matsuwaki et al. [59]
htPA-Cre Neural crest cells No effect on febrile response to IL-1 Matsuwaki et al. [59]
ChAT-Cre Catecholaminergic
neurons
Decreases brain damage after stroke Wong et al. [58]
PF4-Cre Platelets No effect on brain damage after stroke Wong et al. [58]
ColVI-CreER Intestinal
mesenchymal cells
No effect on development of intestinal cancer Koliaraki et al. [60]
Hep-Cre Hepatocytes Reduces liver injury after acute liver failure Gehrke et al. [61]
CD45-Cre Leukocytes No role in IL-1-mediated resistance to Mycobacterium tuberculosis Bohrer et al. [62]
Cdh5-Cre Vascular endothelial
cells
Mediates the anti-tumor properties of T cells. Regulates
IL-1-induced brain inflammation
Lee et al. [63]
Tie2-Cre Endothelial cells Decreases IL-1-induced brain inflammation Liu et al. [44]#
Il1r2 CMV-Cre Ubiquitous deletion Reduces inflammation after arthritis Martin et al. [45]
K14-Cre Ubiquitous deletion NI Unpublished**
For IL-1R1fl/fl mice, all cell-/tissue-specific IL-1R1−/− mice have been generated by IL-1R1fl/fl mouse from Abdulaal et al. [42], except those marked
(*), generated by IL-1R1fl/fl mouse from Robson et al. [41]. #In the study of Liu and collaborators (2019), the following mouse lines have also been
generated: IL-1R1fl/fl x LysM-Cre, IL-1R1fl/fl x CX3CR1-Cre, IL-1R1fl/fl x Camk2a-Cre, IL-1R1fl/fl x Vglut2-Cre, and IL-1R1fl/fl x GFAP-Cre. **IL-
1R2fl/fl mice crossed with K14-Cre mice are reported in the present publication. Cre, constitutive deletion by Cre drivers; Cre-ER, inducible deletion by
Cre-ER drivers; EAE, experimental autoimmune encephalomyelitis; MI, myocardial infarction; NI, not indicated
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response elicited by IL-1, whereas deletion of IL-1R1 on cen-
tral or peripheral neurons (including catecholaminergic neu-
rons and nociceptor sensory neurons) had no noticeable effect
on the febrile response [59]. An interesting work by Knoll and
collaborators [55] confirmed that endothelial IL-1R1 signal-
ing is critical in the establishment of the febrile response to IL-
1, whereas IL-1R1 signaling in microglia of the brain paren-
chyma has no role. Further, endothelial IL-1R1 is essential for
endothelial activation in the context of IL-1-driven brain in-
flammation [44] and a further study using microglial-specific
IL-1R1-deficient mice showed that IL-1 actions on brain en-
dothelia triggers the production of endothelial-derived factors
that are able to activate microglial cells [54]. In the context of
stroke, brain endothelial IL-1R1, but also neuronal IL-1R1, is
critical in mechanisms of cerebrovascular inflammation and
brain damage after experimental cerebral ischemia, whereas
no involvement of IL-1 signaling in peripheral cells, including
platelets on stroke outcome was observed [58].
Finally, little work has been conducted regarding IL-1R2fl/
fl mice, and to date, only ubiquitous constitutive deletion of
IL-1R2 (IL-1R2−/−) has been achieved, including that of our
work. The only work reporting the use of IL-1R2−/− in disease
is that ofMartin and collaborators [45], who demonstrated that
IL-1R2 deletion plays an important inhibitory role on IL-1-
regulated inflammation in a model of arthritis, in accordance
with its known inhibitory function, as recently reviewed [64].
Concluding remarks and future directions
IL-1 is a key cytokine regulating many physiological pro-
cesses as well as the inflammatory responses to infection
or injury, and global constitutive IL-1-deficient mouse
models, which is a fairly recent approach, have to date
helped unraveling key mechanisms of IL-1 actions in dis-
ease but have significant limitations. The recent genera-
tion of new mouse mutants allowing conditional deletion
of IL-1 and its receptors has led to the discovery of un-
expected new mechanisms of inflammation regulated by
IL-1. To date, a limited number of cell-/tissue-specific IL-
1-deficient mice have been generated, and this is mainly
due to the fact that IL-1αfl/fl, IL-1βfl/fl, IL-1R1fl/fl, and IL-
1R2fl/fl mice have only been recently produced. However,
several projects targeting the IL-1 system in other cells/
tissues are currently ongoing. Importantly, to the best of
our knowledge, IL-1Rafl/fl and IL-1RAcPfl/fl mice have
not been generated yet, and future generation of new lines
in which all IL-1 ligands and their receptors can be
targeted in other cell/tissue and other disease models will
lead to new mechanisms to be discovered, providing a
step change in our understanding of IL-1 actions disease
and the potential development of new targeted IL-1
therapies.
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